1H NMR Metabolomic Blood Plasma Analysis for Early Detection of Pancreatic Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F19%3A43919044" target="_blank" >RIV/60461373:22340/19:43919044 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

1H NMR Metabolomic Blood Plasma Analysis for Early Detection of Pancreatic Cancer

Popis výsledku v původním jazyce

Pancreatic cancer (PC) has very high mortality, only 5% of patientssurvive longer than 3–5 years, this is mostly due to late diagnosis.1Nowadays, the PC diagnosis is mainly limited by non-specific earlysymptoms (weakness, nausea, or abdominal pain) and methods withlow sensitivity and specificity.2Consequently, early specific symptomsand characteristic biomarkers remain a subject of intensive research.In our study,1H NMR metabolomics was used to identify changesin the concentration of low molecular metabolites in the blood plasmaof healthy controls, pancreatic cancer patients, long term type 2 dia-betes mellitus patients and individuals with new-onset diabetes. UsingChenomX software, it was possible to quantify 65 metabolites acrossall samples. Subsequently, a statistical analysis (PCA, OPLS-DA,

Název v anglickém jazyce

1H NMR Metabolomic Blood Plasma Analysis for Early Detection of Pancreatic Cancer

Popis výsledku anglicky

Pancreatic cancer (PC) has very high mortality, only 5% of patientssurvive longer than 3–5 years, this is mostly due to late diagnosis.1Nowadays, the PC diagnosis is mainly limited by non-specific earlysymptoms (weakness, nausea, or abdominal pain) and methods withlow sensitivity and specificity.2Consequently, early specific symptomsand characteristic biomarkers remain a subject of intensive research.In our study,1H NMR metabolomics was used to identify changesin the concentration of low molecular metabolites in the blood plasmaof healthy controls, pancreatic cancer patients, long term type 2 dia-betes mellitus patients and individuals with new-onset diabetes. UsingChenomX software, it was possible to quantify 65 metabolites acrossall samples. Subsequently, a statistical analysis (PCA, OPLS-DA,

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10406 - Analytical chemistry

Projekt

<a href="/cs/project/NV16-31028A" target="_blank" >NV16-31028A: Účinnost nových spektroskopických biomarkerů pro detekci časného stádia karcinomu pankreatu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů